Wire open Last filed Pemvidutide MASH responder data show combined liver test gains at 48 weeks RSS
Peptide Zone

Peptide medicine news,
filed as it happens.

Morning wire

Peptide medicine news filed as it happens

Peptide Zone is a news wire for peptide medicines such as GLP-1 drugs, amylin analogues and peptide vaccines. Each story covers one regulator decision, trial readout, industry deal or safety review, names its primary source and says what comes next. Nothing here is medical advice. About the newsroom

UrgentTRLNews

Pemvidutide MASH responder data show combined liver test gains at 48 weeks

At The Liver Meeting 2026, IMPACT trial analyses showed up to 42.9% of patients on pemvidutide met three liver test targets together at 48 weeks, against 3.3% on placebo. The results rest on noninvasive tests, and 48 week safety data were not reported.

DENVER

42.9%Share on the higher pemvidutide dose meeting liver fat, ALT and stiffness targets together at 48 weeks, vs 3.3% on placebo
  1. What's newIMPACT Phase 2b responder analyses showed far more pemvidutide patients than placebo patients improving on several noninvasive liver tests at once after 48 weeks, including 25.8% vs none in the strictest test.
  2. Why it mattersThe composites suggest liver fat, inflammation and fibrosis markers moved together on the drug, but they rest on noninvasive tests that regulators do not accept as surrogate endpoints.
  3. What's nextAltimmune began enrolling the PERFORMA Phase 3 trial in 2026 and expects 52 week biopsy data in 2029, with full approval tied to liver outcomes at about 60 months.

Latest on the wire

Full wire

The 60-second briefing

Five things filed most recently

  1. SAF · 7 Nov 2026Two Baker Donelson attorneys wrote in Healio that physicians who prescribe, source or promote unapproved peptides still face license, criminal, fraud and malpractice exposure after the FDA paused enforcement on six compounded peptides.
  2. REG · 7 Nov 2026A Pharmacy Times review published Nov. 6 says Medicaid coverage of GLP 1 drugs for obesity has narrowed to 13 states while heart and kidney trial evidence grows. Medicare coverage runs through a temporary Bridge to the end of 2027 after CMS delayed the Part D portion of its BALANCE Model.
  3. TRL · 7 Nov 2026MedPage Today reports that Lilly's placebo controlled Phase 3 ATTAIN-OSA program of oral orforglipron, in adults who have obstructive sleep apnea along with excess weight, is a late breaker on Monday, Nov. 9, at the AHA meeting in Chicago.
  4. SAF · 6 Nov 2026The Daily Mail reported patient accounts and published case reports of allodynia, skin that hurts at a light touch, in people taking semaglutide or tirzepatide. Several patients improved after a dose cut or a pause.
  5. REG · 6 Nov 2026A pharmacist's analysis says the interim HHS policy for six compounded peptides cites human studies and a test certificate for BPC 157 without naming or publishing them.

By the numbers

The one figure each story turns on.

20.9% vs 9.4%Average weight loss at 80 weeks on the higher retatrutide dose versus Ozempic, per Lilly TRL · 28 OCT · Retatrutide Ozempic trial shows bigger A1C drop and double the weight loss 28.7%average weight loss on the highest dose after 68 weeks TRL · 11 DEC · Retatrutide posts the largest average weight loss yet in a phase 3 trial 62.9%of treated patients saw liver inflammation resolve without fibrosis worsening, vs 34.3% on placebo REG · 15 AUG · Wegovy gets accelerated approval for fatty liver disease with scarring 20.2%average weight loss on tirzepatide vs 13.7% on semaglutide after 72 weeks TRL · 11 MAY · Tirzepatide beats semaglutide on weight loss head to head 1stprescription drug approved to treat obstructive sleep apnea in adults with obesity REG · 20 DEC · FDA clears tirzepatide as the first medicine for obstructive sleep apnea ~80%Wegovy pill share of new to brand US prescriptions in Q3 2026, as reported by Novo Nordisk IND · 05 NOV · Wegovy pill market share holds near 80 percent as Novo raises outlook

Threads we are following

Storylines that span months. Each dot is a story, placed by date.

Thread · 4 stories

Compounded copies and the rules around them

What can people legally get, and how do regulators react when demand outruns supply?

Dec 2024Nov 2026

  • 21 MARSemaglutide copies arrive as key patents lapse outside the US and Europe
  • 06 JUNEU safety committee adds a rare eye condition to semaglutide warnings

Thread · 6 stories

The incretin race

Who ends up with the most weight loss, the fewest side effects and the easiest dosing?

Dec 2024Nov 2026

  • 22 DECThe first GLP 1 pill for weight management gets the green light
  • 07 AUGThe weight loss pill that is not a peptide posts its first obesity readout

Thread · 4 stories

Beyond the scale

Which organ benefits hold up in outcome trials, and which do not?

Dec 2024Nov 2026

  • 24 NOVWhy semaglutide failed to slow Alzheimer's in the EVOKE trials
  • 28 JANSemaglutide wins a kidney label after the FLOW outcome trial

Desk fronts

REGRegulators12
TRLTrials26
INDIndustry18
SAFSafety26
EXPExplainers4

Where this news came from

Primary source type of every story on the wire. How we label sources

  • Regulator15
  • Journal10
  • Company release22
  • Conference9
  • Our newsroom30